Oral Wegovy Surpasses Eli Lilly's Zepbound as Top-Selling Weight-Loss Drug
Novo Nordisk's oral version of Wegovy became the top-selling weight-loss drug in the U.S., surpassing Eli Lilly’s Zepbound. Oral Wegovy has captured about 89% of prescriptions and attracted new patients to GLP-1 medications, expanding market demand.
Topics: Eli Lilly GLP-1 drugs Novo Nordisk Wegovy weight loss medications Zepbound